 Dear Fellow Investor, The Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged… Defense stocks exploded… And gold ripped past $5,000. But something even bigger just snapped inside the gold market. Wars don't just move markets. They expose broken financial systems. For decades, the price of gold has been controlled by paper contracts traded between the largest banks in the world. But wars create a problem for that system. Because when global tensions rise, investors stop trusting paper promises. They want the real thing. And on March 31st, a legal deadline could force the paper gold market to confront a reality it has hidden for years. When that happens, gold could surge. But the biggest gains won't come from gold itself. They'll come from the tiny companies sitting on massive untapped deposits of the metal. There's one company sitting on more gold than France, Italy, and China combined. And my research suggests it could surge 1,000% as the gold market resets. You can see the evidence — and the ticker symbol — here >>> "The Buck Stops Here," Dylan Jovine, CEO & Founder Behind the Markets
Special Report Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsSubmitted by Nathan Reiff. Article Published: 3/12/2026. 
Key Points- Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: 5 American Billionaires Dumping Dollars
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion over the next eight years. Companies often take a niche approach, developing medicines that target specific cancer types with dedicated mechanisms. A number of promising treatments have shown strong potential—and with that comes the possibility of significant sales. Two smaller biotech companies are experiencing notable share-price momentum thanks to their leading oncology drugs. These treatments not only offer therapeutic promise but could help the firms move past penny-stock status toward greater stability and potential long-term profitability. That said, both companies face substantial challenges, so these remain high-risk, high-reward investments for shareholders willing to take a chance. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle#1 Futurist Calls [THIS] His Best FREE Stock Pick In the next 3 minutes… James Altucher is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO… Click here to watch this short 3-minute video now. Iovance Biotherapeutics Inc. (NASDAQ: IOVA) bucked market trends in early March, rising nearly 37% in a week when the S&P 500 fell roughly 1%. That added to IOVA's year-to-date performance, which has more than doubled. Still, with a consensus price target of $8.88, Wall Street anticipates further upside—that target implies roughly 71% additional gains from current levels. The main catalyst for Iovance's move is Amtagvi, a T-cell immunotherapy for certain types of melanoma. Amtagvi was approved in the United States for melanoma in 2024 and has been gaining momentum in sales and regulatory progress, with additional approvals likely in the E.U., U.K., and elsewhere. When administered with Proleukin, the company's IL-2 immunotherapy, management believes Amtagvi could exceed $1 billion in peak U.S. sales. Amtagvi's bigger opportunity may lie beyond melanoma: the drug received Fast Track Designation from the FDA for non-small cell lung cancer and is being explored against other tumor types. Part of Iovance's outperformance this year reflects its Q4 2025 earnings report, issued in late February, in which the company posted smaller-than-expected losses per share and generated $5 million in revenue. For the full year, revenue rose about 30% year over year. Iovance is considered a penny stock and a relatively small (around $2 billion) biotech. Despite this year's rally, analysts remain cautious—roughly half of its ratings are Holds or Sells. Risks are significant: beyond the usual vulnerabilities of smaller biotechs, Amtagvi's personalized and complex manufacturing process makes scaling expensive and challenging. That could limit Iovance's ability to generate consistent profits even if demand increases. Massive Sales Growth for ImmunityBio's Bladder Cancer DrugWhile ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, its year-to-date performance far outpaces Iovance's. IBRX shares are up nearly 300% in 2026, and analysts remain optimistic: the consensus price target is $13.60, roughly 70% above the current share price even after the recent run. ImmunityBio's primary growth driver is Anktiva, a treatment for certain types of bladder cancer. In February, shares jumped after the E.U.'s regulator granted the drug conditional marketing authorization—the latest in a series of approvals worldwide. Anktiva is already driving revenue growth, with the company reporting $113 million in sales last year, a roughly 700% year-over-year increase. Like Amtagvi, Anktiva may have potential in other cancer indications; ImmunityBio is actively exploring additional uses. Despite the dramatic gains over recent quarters, IBRX remains a speculative investment. The company reported a sizable full-year net loss of $351 million for 2025 as R&D spending remained high. Wall Street analysts are somewhat more bullish on ImmunityBio than on Iovance—six of seven analysts rate the stock a Buy or equivalent—but risks and volatility persist. | 
Tidak ada komentar:
Posting Komentar